At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 342 enrolled
Drug / intervention
Meningococcal vaccine GSK134612 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers
In Brief
A Phase 3 clinical trial evaluating Meningococcal vaccine GSK134612 and Meningitec™ for Infections, Meningococcal. Completed, enrolled 342 participants across 14 sites.
Detailed Summary
Subjects were previously vaccinated at 12 to 23 months of age. This extension study starts 24 months after vaccination and the subjects who were vaccinated in the primary study will be enrolled in this extension phase. No new subjects will be enrolled.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesFinland
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartAug 2009
Primary CompletionDec 2009
Study CompletionSep 2012
TodayJul 2026
First PostedAug 10, 2009
Enrollment StartAug 25, 2009
Primary CompletionDec 16, 2009
Study CompletionSep 10, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.9 years ago
Interventions
Meningococcal vaccine GSK134612biological
One intramuscular dose (Booster)
Meningitec™biological
One intramuscular dose (Booster)